ImmuPharma has appointed Kymos Group as the bioanalytical partner for its diabetes drug candidate Kapiglucagon, completing its outsourced development team. Kymos will develop and validate methods to measure the drug in biological samples and analyze data from preclinical and planned Phase 1 trials. This follows earlier contracts with Thermo Fisher and Bachem AG for manufacturing and active ingredient production. These partnerships prepare ImmuPharma to file an investigational new drug application in the US, advancing Kapiglucagon towards clinical testing. The drug aims to improve dual-hormone artificial pancreas systems for Type 1 diabetes by overcoming glucagon formulation challenges. The development is funded by a £6.47 million raise and targets a two-year plan, with the autoimmune platform P140 remaining the group's main value driver.
FLSmidth & Co. A/S continued its share buy-back program initiated on 18 May 2026, repurchasing 61,000 shares between 3 and 7 August 2026 at prices ranging from DKK 487.45 to DKK 511.77 per share. This brings the total shares bought back under the pro...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early August 2026, the bank has repurchased shares worth approximately DKK 1.57 billion at an average price of D...
Jyske Bank has continued its share repurchase program initiated in February 2026, acquiring shares valued at approximately DKK 1.57 billion by early August 2026. The program, which runs until January 29, 2027, allows the bank to buy back shares up to...
Quadient has been named among the leading providers in The Forrester Wave™: Accounts Payable Invoice Automation Software, Q2 2026, marking its first inclusion in this key industry evaluation. The recognition highlights Quadient's growing presence and...
Bitcoin ETFs attracted $853.54 million in inflows during the first week of August, marking their strongest weekly performance since April 17. Blackrock's IBIT fund was the main driver, contributing over 80% of the inflows, while Ether ETFs also gaine...
